MX2016007407A - Peptidos resistentes a proteasa. - Google Patents

Peptidos resistentes a proteasa.

Info

Publication number
MX2016007407A
MX2016007407A MX2016007407A MX2016007407A MX2016007407A MX 2016007407 A MX2016007407 A MX 2016007407A MX 2016007407 A MX2016007407 A MX 2016007407A MX 2016007407 A MX2016007407 A MX 2016007407A MX 2016007407 A MX2016007407 A MX 2016007407A
Authority
MX
Mexico
Prior art keywords
peptides
methyl
protease
alpha
resistant peptides
Prior art date
Application number
MX2016007407A
Other languages
English (en)
Spanish (es)
Inventor
Revell Jefferson
Bednarek Maria
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of MX2016007407A publication Critical patent/MX2016007407A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/62Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/605Glucagons
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575Hormones
    • G01N2333/605Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MX2016007407A 2013-12-13 2014-12-10 Peptidos resistentes a proteasa. MX2016007407A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361915662P 2013-12-13 2013-12-13
PCT/EP2014/077240 WO2015086686A2 (en) 2013-12-13 2014-12-10 Protease resistant peptides

Publications (1)

Publication Number Publication Date
MX2016007407A true MX2016007407A (es) 2016-12-12

Family

ID=52021207

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016007407A MX2016007407A (es) 2013-12-13 2014-12-10 Peptidos resistentes a proteasa.

Country Status (11)

Country Link
US (1) US20160318987A1 (enExample)
EP (2) EP3415526A1 (enExample)
JP (1) JP2017502003A (enExample)
KR (1) KR20160098406A (enExample)
CN (1) CN105849123A (enExample)
AU (1) AU2014363547A1 (enExample)
BR (1) BR112016013157A2 (enExample)
CA (1) CA2933405A1 (enExample)
MX (1) MX2016007407A (enExample)
SG (1) SG10201805039UA (enExample)
WO (1) WO2015086686A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI726889B (zh) 2015-06-10 2021-05-11 英商梅迪繆思有限公司 蛋白酶抗性之脂化肽
CA3003465A1 (en) 2015-10-28 2017-05-04 Krishna Kumar Novel polypeptides with improved proteolytic stability, and methods of preparing and using same
CA3025592A1 (en) 2016-06-09 2017-12-14 Medimmune Limited Protease-resistant mono-lipidated peptides
EP4092038A1 (en) 2017-09-11 2022-11-23 Protagonist Therapeutics, Inc. Opioid agonist peptides and uses thereof
PE20211417A1 (es) 2018-04-05 2021-08-02 Sun Pharmaceutical Ind Ltd Analogos novedosos de glp-1
CN115348876A (zh) * 2020-03-31 2022-11-15 安塔罗斯医疗公司 用于成像和治疗目的的包含螯合部分的选择性gip受体激动剂
CN116685599A (zh) * 2020-12-16 2023-09-01 免疫医疗有限公司 多肽及其用途
TW202346323A (zh) * 2022-02-07 2023-12-01 英商梅迪繆思有限公司 具有改善的生物穩定性的glp—1及升糖素雙重激動肽

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG125915A1 (en) * 1998-12-07 2006-10-30 Sod Conseils Rech Applic Analogues of glp-1
PT1987052E (pt) * 2006-02-08 2011-07-25 Lonza Ag Síntese de péptidos tipo glucagina
EP2021014A1 (en) * 2006-05-26 2009-02-11 Brystol-Myers Squibb Company Sustained release glp-1 receptor modulators
WO2008023050A1 (en) * 2006-08-25 2008-02-28 Novo Nordisk A/S Acylated exendin-4 compounds
CA2707448C (en) * 2007-12-11 2014-10-14 Cadila Healthcare Limited Peptidomimetics with glucagon antagonistic and glp-1 agonistic activities
EP2110380B1 (en) * 2008-04-18 2010-11-10 F. Hoffmann-La Roche AG Alpha-N-methylation of amino acids
WO2011048614A2 (en) * 2009-10-22 2011-04-28 Cadila Healthcare Limited Short chain peptidomimetics based orally active glp-1 agonist and glucagon receptor antagonist
US20130143800A1 (en) * 2011-11-07 2013-06-06 Research Development Foundation Combination therapies to treat diabetes
AR092873A1 (es) * 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
WO2014088631A1 (en) * 2012-12-06 2014-06-12 Stealth Peptides International, Inc. Peptide therapeutics and methods for using same

Also Published As

Publication number Publication date
WO2015086686A2 (en) 2015-06-18
CA2933405A1 (en) 2015-06-18
KR20160098406A (ko) 2016-08-18
JP2017502003A (ja) 2017-01-19
WO2015086686A3 (en) 2015-10-29
EP3080153A2 (en) 2016-10-19
BR112016013157A2 (pt) 2017-09-26
SG10201805039UA (en) 2018-07-30
CN105849123A (zh) 2016-08-10
US20160318987A1 (en) 2016-11-03
EP3415526A1 (en) 2018-12-19
AU2014363547A1 (en) 2016-06-30

Similar Documents

Publication Publication Date Title
CY1125302T1 (el) Συναγωνιστες γλυκαγονης και glp-1 για την αγωγη της παχυσαρκιας
MX2016007407A (es) Peptidos resistentes a proteasa.
EA202090919A1 (ru) Липидные наночастицы для доставки модифицированной рнк, кодирующей полипептид vegf-a
MX2013013913A (es) Polipeptidos.
MX2021005254A (es) Produccion recombinante de una preparacion de peptido de colageno y uso de la misma.
NZ705370A (en) Fcγriib-specific fc region variant
MX2017009595A (es) Compuestos antisenescentes y usos de los mismos.
MX351414B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico.
MX2016008355A (es) Anticuerpos que comprenden extensiones de polipeptidos de cadena ligera en el extremo c y conjugados y metodos de uso de estos.
MX2018012166A (es) Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1).
EA201990071A1 (ru) Композиция пептидной вакцины
MX2017006866A (es) Pares de unión para producción de péptidos.
CR20130667A (es) Composiciones que contienen, mètodos que involucran, y usos derivados de dolastatina unidos a aminoàcidos no naturales
EA201890815A1 (ru) Аминокислотные композиции с модифицированным высвобождением для перорального введения
PH12018502465A1 (en) Mic-1 compounds and use thereof
PH12017502259A1 (en) Protease-resistant lipidated glp-1 analogs
MX2018014966A (es) Peptidos monolipidados resistentes a proteasas.
EA201692439A1 (ru) Пролин-специфичная эндопротеаза и ее применение
MX354156B (es) Dipeptido que comprende un aminoacido no proteogenico.
NZ596501A (en) Casb7439 constructs
EA201590601A1 (ru) Применение pedf-производных полипептидов для лечения остеоартрита
MX2015002279A (es) Peptido pntx(19) sintético, composición farmacéutica.y uso.
NZ732301A (en) Peptide compound, preparation method therefor, and application thereof
EP3925968A3 (en) Hsp70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cell
TWI407915B (enExample)